PCSK9 inhibition could ameliorate atherosclerosis and thus cardiovascular disease by immune mechanisms that are unrelated to lowering of low-density lipoprotein (LDL) cholesterol, according to new research.
PCSK9 inhibition could ameliorate atherosclerosis and thus cardiovascular disease by immune mechanisms that are unrelated to lowering of low-density lipoprotein (LDL) cholesterol, according to new research.